Our partner is focused on developing next-generation therapies using their peptide technology. Their innovative approach targets specific disease-causing proteins, particularly in cancer, to deliver more effective and precise treatments, aiming to improve patient outcomes.

This critical hire utilized their extensive expertise in developing bispecific immuno-oncology agents, as well as toxin conjugate therapeutics for cancer and other serious diseases to drive our partner's success. They were responsible for designing and driving clinical development plans for our client's pipeline candidates, all of which represented first-in-class or best-in-class therapies.